Nimotuzumab with chemo and radiation for advanced nose cancer
Treatments studied
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This trial tests whether adding nimotuzumab (an anti-EGFR antibody) to standard chemotherapy and radiation can improve outcomes for people with advanced nasopharyngeal carcinoma. It may help the cancer respond better and control it more effectively after treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 to 70
- Your nose cancer type is non-keratinizing carcinoma
- Your cancer is stage III to IV (with an exception for T3N0) and can be measured on scans
- Your general health is good enough (ECOG 0 to 1)
- Your blood counts, liver tests, and kidney function are within required ranges
- You have not had surgery to remove the main tumor or lymph nodes (except a biopsy)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs—nimotuzumab (a targeted therapy) and TGP (a chemotherapy)—as a first treatment for people whose nasopharyngeal cancer has returned or spread. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial tests two different chemotherapy combinations, each given with two extra drugs (one that targets cancer cells and one that boosts your immune system). It's for people with advanced nasopharyngeal cancer who haven't been treated yet, and it aims to see which combination works better.
This trial tests a new treatment plan for a specific type of advanced nasopharyngeal cancer. It combines chemotherapy and radiation to see if it can improve outcomes for people with high-risk stage III disease.
This trial tests a new drug combination called GNT given before standard chemoradiation for people with locally advanced nasopharyngeal cancer. It aims to improve treatment outcomes.
This trial tests a new combination of an immunotherapy drug (tislelizumab) plus standard chemoradiotherapy for people with advanced nasopharyngeal carcinoma. It aims to find out if this combination is more effective than standard care alone.
This trial tests a combination of three drugs as a first treatment for people with locally advanced nasopharyngeal cancer. It aims to see if the treatment shrinks tumors before standard therapy.
Hear when a new Nasopharyngeal Carcinoma by AJCC V8 Stage trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.